
Current Price | $0.63 | Mkt Cap | $2.4M |
---|---|---|---|
Open | $0.64 | P/E Ratio | -0.09 |
Prev. Close | $0.63 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.61 - $0.65 | Volume | 16,448 |
52-Wk Range | $0.60 - $14.18 | Avg. Daily Vol. | 279,252 |
Current Price | $0.63 | Mkt Cap | $2.4M |
---|---|---|---|
Open | $0.64 | P/E Ratio | -0.09 |
Prev. Close | $0.63 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.61 - $0.65 | Volume | 16,448 |
52-Wk Range | $0.60 - $14.18 | Avg. Daily Vol. | 279,252 |
The best Bull and Bear pitches based on recency and number of recommendations.
There are no pitches that meet the Top Bull criteria. Explain
If this upsets you, start recommending pitches below!
Speculation on buyouts aside, I think it’s clear that Galmed has a long road ahead of it. It has to successfully complete its phase 2 trials, then fund and complete phase 3 trials, then obtain regulatory approval, then undergo a significant… More
Read the most recent pitches from players about GLMD.
Recs
Arrest and Arrive studies will both show positive results and ultimately will lead to a buy out from Gilead.
Recs
Speculation on buyouts aside, I think it’s clear that Galmed has a long road ahead of it. It has to successfully complete its phase 2 trials, then fund and complete phase 3 trials, then obtain regulatory approval, then undergo a significant transformation from a research organization, and then go on to succeed in a medical niche whose size isn’t really well understood. It's hard to know how much capital (read shareholder dilution) all of that will require. And even then, the company will likely only have about 5 years of regulatory exclusivity before generics begin moving in, and presumably it’ll be funneling a lot of that revenue into more trials for expanded usage and additional conditions and diseases.
Recs
BP 5 TP 24, NICE UPSIDE POTENTIAL
Find the members with the highest scoring picks in GLMD.
DavidSobel (< 20) Score: +336.19
The Score Leader is the player with the highest score across all their picks in GLMD.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
nevercontent | 55.88 | 10/22/2015 |
![]() |
3Y | $9.54 | -93.40% | +109.93% | +203.33 | 1 Comment | |
warrenout2 | 96.23 | 11/14/2016 |
![]() |
5Y | $3.50 | -82.00% | +98.32% | +180.32 | 0 Comment | |
downwithpumpers | 96.94 | 8/4/2017 |
![]() |
5Y | $6.92 | -90.90% | +73.89% | +164.78 | 0 Comment | |
zzlangerhans | 99.35 | 12/13/2017 |
![]() |
1Y | $8.86 | -92.89% | +61.18% | +154.07 | 0 Comment | |
WildShaman | 77.64 | 7/5/2018 |
![]() |
5Y | $11.69 | -94.61% | +58.14% | +152.75 | 0 Comment | |
TMFGBudwell | < 20 | 6/14/2018 |
![]() |
5Y | $18.00 | -96.50% | +54.27% | +150.77 | 0 Comment | |
roolbreakers | 94.25 | 7/13/2018 |
![]() |
5Y | $14.86 | -95.76% | +53.92% | +149.68 | 0 Comment | |
jonboy13 | 93.67 | 11/24/2021 |
![]() |
5Y | $2.53 | -75.10% | -8.10% | +67.00 | 0 Comment | |
kfassini | < 20 | 2/26/2021 |
![]() |
5Y | $3.95 | -84.05% | +12.98% | -97.03 | 0 Comment | |
gunda7907 | < 20 | 12/27/2019 |
![]() |
5Y | $5.92 | -89.36% | +32.95% | -122.31 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.